刘毅铭

Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.

Cooley advised Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, on its nondilutive financings of up to $250 million with Sagard Healthcare Partners.

Cooley advised Beihai Biotech, an innovative biopharmaceutical company, on its exclusive licensing, supply and commercialization agreement with Zydus Lifesciences for BEIZRAY.

Cooley advised the sponsors and underwriters of BrainAurora Medical Technology, a provider of medical diagnostics and digital therapies, in connection with the company’s HK$583 million initial public offering.

Cooley advised Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, on its $120 million Series C.